

October 19, 2021

BSE Limited Floor 25, P. J. Towers Dalal Street, Fort Mumbai - 400 001 National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051

Dear Sirs,

In terms of Regulations 30, 33 and 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2021 were approved by the Board of Directors of the Company at its meeting held today at 12:15 p.m. and concluded at 02.20 pm.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

- 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended September 30, 2021;
- 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and;
- 3. Copies of the Press Release and Presentation

We request you to take the same on records.

Thanking you,

Yours faithfully, For Jubilant Ingrevia Limited

Deepanjali Gulati Company Secretary Encl.: as above

A Jubilant Bhartia Company



Jubilant Ingrevia Limited 1-A, Sector 16-A, Noida-201 301, UP, India Tel: +91 120 4361000 Fax: +91 120 4234895-96 www.jubilantingrevia.com Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223 Uttar Pradesh, India CIN : L24299UP2019PLC122657

Walker Chandiok & Co LLP 21st Floor, DLF Square

Jacaranda Marg, DLF Phase II, Gurugram - 122002 Haryana, India **T** +91 124 462 8099 **F** +91 124 462 8001

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

- 1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Jubilant Ingrevia Limited ('the Company') for the quarter ended 30 September 2021 and the year to date results for the period 1 April 2021 to 30 September 2021, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the figures for the corresponding quarter and year-to-date period ended 30 September 2020, as reported in the Statement, have been approved by the Company's Board of Directors, but have not been subjected to audit or review. Attention is drawn to the fact that the cash flow figures for the corresponding half year ended 30 September 2020 have been approved by the Company's Board of Directors but have not been subjected to audit or review.
- 2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5. We draw attention to note 5 of the accompanying Statement, which represents supplementary information relating to the operations of the life science ingredients business for the corresponding periods i.e., quarter and year-to-date period ended 30 September 2020 and for the period from 1 April 2020 to 31 January 2021, which has been prepared by the management of the Company and has not been subjected to an audit or a review by us. Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013

Ashish Gupta Partner Membership No. 504662 eSigned using Cloud DSC (Leegality.com - 1YJN7pC) Ashish Gupta Date: Tue Oct 19 13:55:48 IST 2021



UDIN: 21504662AAAAIA8556

Place: New Delhi Date: 19 October 2021

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30 September 2021

							(₹ in Lakhs)
			Quarter Ended	I	Half Yea	r Ended	Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
Sr. No.	. Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2021	2021	2020	2021	2020	2021
1	Revenue from operations						
	a) Sales/Income from operations	123137	109935	-	233072	-	66377
	b) Other operating income	550	608	-	1158	-	516
	Total revenue from operations	123687	110543	-	234230	-	66893
2	Other income	696	592	-	1288	-	245
3	Total income (1+2)	124383	111135	-	235518	-	67138
4	Expenses						
	a) Cost of materials consumed	73706	60822	-	134528	-	36346
	b) Purchases of stock-in-trade	4120	2585	-	6705	-	1452
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(3076)	(4063)	-	(7139)	-	993
	d) Employee benefits expense	6634	7242	-	13876	-	4311
	e) Finance costs	1097	1676	-	2773	-	945
	f) Depreciation and amortisation expense	2956	3061	-	6017	-	2135
	g) Other expenses:						
	- Power and fuel expense	10350	8739	-	19089	-	5279
	- Others	10581	10746	-	21327	-	8829
	Total expenses	106368	90808	-	197176	-	60290
5	Profit before exceptional items and tax (3-4)	18015	20327	-	38342	-	6848
6	Exceptional items	-	-	-	-	-	1294
7	Profit before tax (5-6)	18015	20327	-	38342	-	5554
8	Tax expense			-		-	
	- Current tax	3095	3541	-	6636	-	971
	- Deferred tax charge	2664	2969	-	5633	-	724
9	Net profit for the period (7-8)	12256	13817	-	26073	-	3859
10	Other comprehensive income (OCI)						
	i) a) Items that will not be reclassified to profit or loss	(279)	34	-	(245)	-	(33)
	b) Income tax relating to items that will not be reclassified to profit or loss	97	(12)	-	85	-	12
	ii) a) Items that will be reclassified to profit or loss	-	-	-		-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
11	Total comprehensive income for the period (9+10)	12074	13839	-	25913	-	3838
12	Earnings per share of ₹ 1 each (not annualised)						
	Basic (₹)	7.69	8.67	-	16.37	-	14.75
	Diluted (₹)	7.69	8.67	-	16.37	-	14.75
13	Paid-up equity share capital (face value per share ₹1)	1593	1593	5	1593	5	1593
14	Reserves excluding revaluation reserves (other equity)	1555	1999	5	181402	(17)	155992
14					161402	(17)	192995
	See accompanying notes to the Standalone Unaudited Financial Results						



Statement of Standalone Unaudited Assets and Liabilities

		1 Ac.++	(₹ in Lakh: As at	
Sr. No.	Particulars	As at	31 March	
Sr. NO.	Farticulars	30 September		
		(Unaudited)	(Audited)	
		2021	2021	
Α	ASSETS			
1.	Non-current assets			
1.		10704	1645	
	Property, plant and equipment	163764	1645	
	Capital work-in-progress	9120	62	
	Intangible assets	376	4	
	Intangible assets under development	321	1	
	Right-of-use assets Financial assets:	7588	76	
	Investment in subsidiaries and associate	13490	134	
		49		
	Loans Other financial courts		7	
	Other financial assets	282 89	2	
	Income-tax assets (net)	1	1.4	
	Other non-current assets Total non-current assets	1689	14	
	lotal non-current assets	196768	1944	
2.	Current assets			
	Inventories	62758	520	
	Financial assets:			
	Trade receivables	63614	480	
	Cash and cash equivalents	3909	65	
	Other bank balances	1966	19	
	Loans	51		
	Other financial assets	7042	50	
	Other current assets	17262	157	
	Total current assets	156602	1295	
	Total assets	353370	3239	
в	EQUITY AND LIABILITIES			
1.	Equity			
	Equity share capital	1593	15	
	Other equity	181402	1559	
	Total equity	182995	1575	
2.	Liabilities			
	Non-current liabilities			
	Financial liabilities:			
	Borrowings	38018	646	
	Lease liabilities	4098	42	
	Provisions	6729	66	
	Deferred tax liabilities (net)	8519	27	
	Total non-current liabilities	57364	783	
	Current liabilities			
	Financial liabilities:			
	Borrowings	7850	89	
	Lease liabilities	295	-	
	Trade payables		_	
	Total outstanding dues of micro enterprises and small enterprises	1082	12	
	Total outstanding dues of creditors other than micro enterprises and small enterprises	77662	676	
	Other financial liabilities	4457	69	
	Other current liabilities	16129	17	
	Provisions	1660	11	
	Current tax liabilities (net)	3876	1.	
	Total current liabilities	113011	880	
		353370	000	



Jubilant Ingrevia Limited Note 1: Statement of Standalone Unaudited Cash Flows

		(₹ in lakhs)
	Half Yea	r Ended
Particulars	30 September	30 September
ash flows from operating activities	(Unaudited)	(Unaudited)
	2021	2020
A. Cash flows from operating activities		
Profit before tax	38342	-
Adjustments:		
Depreciation and amortisation expense	6017	-
Loss on sale/disposal/discard of property, plant and equipment (net)	402	-
Finance costs	2773	-
Share-based payment expense	55	-
Unrealised foreign exchange loss (net)	268	-
Interest income	(68)	-
	9447	-
Operating cash flows before working capital changes	47789	-
Increase in trade receivables, loans, other financial assets and other assets	(19202)	-
Increase in inventories	(10695)	-
Increase in trade payables, other financial liabilities, other liabilities and provisions	23339	-
Cash generated from operations	41231	-
Income-tax paid (net of refund)	(2760)	-
Net cash generated from operating activities	38471	-
B. Cash flows from investing activities		
Purchase of property, plant and equipment, intangible assets		
(including capital work-in-progress and intangible assets under development)	(9381)	-
Proceeds from sale of property, plant and equipment	137	-
Investment made in subsidiary	(1)	-
Movement in other bank balances	(19)	-
Interest received	54	-
Net cash used in investing activities	(9210)	-
C. Cash flows from financing activities		
Repayment of long-term borrowings	(32969)	-
Payment of principal balances of lease liabilities	(320)	-
Proceeds from short-term borrowings (net)	4500	
Proceeds from loans taken from subsidiaries	500	-
Dividend paid	(552)	
Finance costs paid (including interest on lease liabilities)	(3080)	-
Net cash used in financing activities	(31921)	-
Net decrease in cash and cash equivalents (A+B+C)	(2660)	-
Add: cash and cash equivalents at the beginning of the period	6569	ç
Cash and cash equivalents at the end of the period	3909	5



Note2: Standalone Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Half Year Ended 30 September 2021

							(₹ in Lakhs)
			Quarter Ended		Half Yea	ar Ended	Year Ended
Sr. No.	Particulars	30 September	30 June	30 September	30 September	30 September	31 March
Sr. 110.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2021	2021	2020	2021	2020	2021
1	Segment revenue						
	a. Speciality Chemicals	37814	37473		75287		24980
	b. Nutrition & Health Solutions	19319	16150	-	35469	-	11355
	c. Life Science Chemicals	79246	68945	-	148191		36848
	Total	136379	122568	-	258947		73183
	Less : Inter segment revenue	12692	12025	-	24717		6290
	Total revenue from operations	123687	110543		234230	-	66893
	a. Speciality Chemicals	28153	29182	-	57335	-	19850
	b. Nutrition & Health Solutions	19319	16150	-	35469	-	11355
	c. Life Science Chemicals	76215	65211	-	141426	-	35688
	Total	123687	110543	-	234230	-	66893
2	Segment results (profit before tax, exceptional items and interest from each segment)						
	a. Speciality Chemicals	5391	6162	-	11553	-	2460
	b. Nutrition & Health Solutions	3424	1563	-	4987	-	1766
	c. Life Science Chemicals	10980	15021	-	26001	-	3805
	Total	19795	22746	-	42541	-	8031
	Less: i. Interest (finance costs)	1097	1676	-	2773		945
	ii. Exceptional items and un-allocable expenditure (net of un-allocable income)	683	743	-	1426		1532
	Profit before tax	18015	20327	-	38342		5554
3	Segment assets						
	a. Speciality Chemicals	157654	157375	-	157654	-	145360
	b. Nutrition & Health Solutions	40308	36665	-	40308	-	36934
	c. Life Science Chemicals	131478	134326	-	131478	-	115045
	d. Unallocable corporate assets	23930	24784	5	23930	5	26658
	Total segment assets	353370	353150	5	353370	5	323997
4	Segment liabilities						
	a. Speciality Chemicals	24002	28856	-	24002	-	33690
	b. Nutrition & Health Solutions	13529	8829	-	13529	-	8008
	c. Life Science Chemicals	73820	69685		73820	-	47166
	d. Unallocable corporate liabilities	59024	74334	17	59024	17	77548
	Total segment liabilities	170375	181704	17	170375	17	166412



Note3: Additional disclosure as per Regulation 52 (4) and 54 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Standalone)

			Quarter Ended		Half Yea	Year Ended	
		30 September	30 June	30 September	30 September	30 September	31 March
Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2021	2021	2020	2021	2020	2021 ##
1	Debt service coverage ratio (in times)# Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts} (EBITDA: Profit before tax + depreciation and amortisation expense + finance costs + exceptional items)	11.37	6.70	-	6.83	-	4.22
2	Interest service coverage ratio (in times) Definition: EBITDA/finance costs	20.12	14.96	-	17.00	-	10.51
3	Bad debts to account receivable ratio (%)# Definition: Bad debts/average of opening and closing trade receivables (Bad debts: Impairment balance as per statements of profit and loss) (Accounts receivables: Trade receivables as per balance sheet)	0.07%	-	-	0.09%	-	0.10%
4	Debtors turnover (in times)# Definition: Revenue from operations/average of opening and closing trade receivables	2.01	2.06	-	4.20	-	1.36
5	Inventory turnover (in times)# Definition: Cost of goods sold/average of opening and closing inventories	1.12	0.96		2.34	-	0.66
6	Operating margin (%) Definition: Operating profit/revenue from operations (Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - other expenses - depreciation and amortisation expense) (Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in	14.89%	19.37%		17.00%	-	9.35%
7	inventories of finished goods, stock-in-trade and work-in-progress} Net profit margin (%) Definition: Net profit for the period/total income	9.85%	12.43%	-	11.07%	-	5.75%
8	Paid-up debt capital (In ₹ Lakhs) Definition: Secured Rated Listed Redeemable Non-Convertible Debentures (Gross of debt initiation cost)	10000			10000		10000
9 10	Net worth (In ₹ Lakhs) Debt equity ratio (in times) Definition: Net debts/net worth {Net debts: Long term borrowings (including current maturities and gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances}	182995 0.22			182995 0.22		157585 0.41
11	Current ratio (in times)	1.39			1.39		1.47
12	Definition: Current assets/current liabilities Long term debt to working capital (in times) Definition: Long term debt/working capital {Long term debt: Long term borrowings (including current maturities and gross of transaction costs}	0.87			0.87		1.56
13	{working capital: Current assets - current liabilities} Current liability ratio (in times) Definition: Current liabilities/total liabilities	0.66			0.66		0.53
14	Total debts to total assets (in times)# Definition: Total debts/total assets {Total debts: Long term borrowings (including current maturities and gross of transaction costs + short term borrowings)	0.13			0.13		0.23
15 # not ann	Fixed assets coverage ratio (in times) Definition: Total assets secured by a first pari-passu charge / indebtedness secured by or agreed to be secured by first charge over fixed assets (i.e. aggregate external borrowing)	10.63			10.63		4.26

not annualised

Figures for the year ended 31 March 2021 are not comparable as it represents only two months of operations of Life Science Ingredients business from 1 February 2021 to 31 March 2021 (refer note 9 for further details).



- 4. The Company has considered the possible effects that may result from the Covid-19 pandemic, on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions, the Company has, as at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the Company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of these assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.
- 5. Pursuant to the Composite Scheme, the Life Science Ingredients business ("LSI business") of Jubilant Pharmova Limited got demerged into the Company with effect from 1 February 2021, accordingly, the standalone financial results of the Company for quarter and year ended 31 March 2021 includes only two months of operations of LSI business from 1 February 2021 to 31 March 2021. Therefore, in order to present the actual scale of operation of the LSI business, the management has presented, in addition to, the standalone financial results of the Company, the following financial information which has been derived/extracted from the financial results of the transferor company, Jubilant Pharmova Limited, to the extend related to LSI business, for respective periods presented, which has not been separately subjected to audit or review and has been presented as 'unaudited' supplementary information:

			(₹ in Lakhs)		
	Quarter Ended	Half Year Ended	Year Ended		
	30 September (Unaudited) 2020	30 September	31 March		
Particulars		(Unaudited) (Unaudite	(Unaudited) (Unaudited)		(Unaudited)
		2020 2020			
	(3 months)	(6 months)	(10 months)		
i) Total revenue from operations	76075	151470	270950		
ii) Other income	1289	2187	3517		
iii) Total income	77364	153657	274467		
iv) Total expenses	69841	139026	246662		
v) Profit before tax	7523	14631	27805		
vi) Tax expenses	1260	3164	6153		
vii) Net profit for the period	6263	11467	21652		

- 6. On 8 October 2021, the Company has entered into Share Purchase, Subscription and Shareholder's Agreement with AMP Energy C&I Private Limited and AMP Energy Green Fifteen Private Limited for acquisition of 26.60% stake of AMP Energy Green Fifteen Private Limited for putting up the solar power plant with capacity of 15.5 MW for Captive Power Consumption.
- 7. During the quarter ended 30 September 2021, the Company has granted 41867 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Company.
- 8. The Secured Rated Listed Redeemable Non-Convertible Debentures (NCDs) aggregating to ₹10000 lakhs outstanding as at 30 September 2021 are secured by a first pari-passu charge created by way of mortgage on certain immovable assets and hypothecation on entire movable property, plant and equipment, both present and future, of the Company. On 6 May 2021, CRISIL Limited has assigned the rating of "CRISIL AA/ Stable" to the said NCDs. The asset cover thereof based on agreed methodology exceeds 100% of the outstanding principal amount of the said NCDs.

Details of due dates for payment of interest and repayment of principal of NCDs are as follows:

Particulars	Previous Due Date		Next Dı	ie Date
	Principal	Interest	Principal	Interest
1000 – 7.90% Non - Convertible Debentures of ₹10 lakhs each	-	2 June 2021*	2 June 2023	2 June 2022

*Interest due on 2 June 2021 has been paid on the due date

- 9. The figures for the quarter ended 30 September 2021 and half year ended 30 September 2021 are not comparable with previous periods since the figures for quarter and half year ended 30 September 2020 is without the results of LSI business and the figures for the year ended 31 March 2021 include results of demerged LSI business from Jubilant Pharmova Limited for two months, from the effective date of demerger i.e., 1 February 2021 till 31 March 2021. Further, figures for quarter and half year ended 30 September 2020 have not been subjected to audit or review by the Statutory Auditors as they are for the period before listing of the Company i.e. 19 March 2021.
- 10. Previous period figures have been regrouped /reclassified to conform to the current period's classification.
- 11. The above standalone unaudited financial results were subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 19 October 2021. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on standalone financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited



Rajesh Kumar Srivastava CEO & Managing Director

 \bigcirc

Walker Chandiok & Co LLP

21st Floor, DLF Square Jacaranda Marg, DLF Phase II, Gurugram - 122002 Haryana, India **T** +91 124 462 8099 **F** +91 124 462 8001

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

- 1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Jubilant Ingrevia Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associate (refer Annexure 1 for the list of subsidiaries and associate included in the Statement) for the quarter ended 30 September 2021and the consolidated year to date results for the period 1 April 2021 to 30 September 2021, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the consolidated figures for the corresponding quarter and year-to-date period ended 30 September 2020, as reported in the Statement, have been approved by the Holding Company's Board of Directors but have not been subjected to audit or review. Attention is drawn to the fact that the cash flow figures for the corresponding half year ended 30 September 2020 have been approved by the Holding Company's Board of Directors but have not been subjected to audit or review.
- 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.



Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

- 4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of review report of other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5. The Statement includes the Group's share of net loss after tax of ₹ 2 lakhs and ₹ 3 lakhs and total comprehensive loss of ₹ 2 lakhs and ₹ 3 lakhs, for the quarter and year-to-date period ended on 30 September 2021, respectively, as considered in the accompanying Statement, in respect of an associate, whose interim financial information have not been reviewed by us. This interim financial information has been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor.

6. We draw attention to Note 5 of the accompanying Statement, which represents supplementary information relating to the operations of the life science ingredients business for the corresponding periods i.e., quarter and year-to-date period ended 30 September 2020 and for the period from 1 April 2020 to 31 January 2021, which has been prepared by the management of the Holding Company and has not been subjected to an audit or a review by us. Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013

Ashish Gupta Partner Membership No. 504662 eSigned using Cloud DSC (Leegality.com - 3YzN3f2) Ashish Gupta Date: Tue Oct 19 13:53:26 IST 2021



UDIN: 21504662AAAHZ3406

Place: New Delhi Date: 19 October 2021 Annexure 1 to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Annexure 1

List of entities included in the Statement

S. No.	Name	Relationship with the Holding Company
1	Jubilant Infrastructure Limited	Subsidiary
2	Jubilant Crop Protection Limited	Subsidiary (with effect from 2 June 2021)
3	Jubilant Life Sciences (USA) Inc.	Subsidiary
4	Jubilant Life Sciences NV	Subsidiary
5	Jubilant Life Sciences International Pte. Limited	Subsidiary
6	Jubilant Life Sciences (Shanghai) Limited	Subsidiary
7	Jubilant Ingrevia Employee Welfare Trust	Subsidiary
8	Mister Veg Foods Private Limited	Associate



Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30 September 2021

							(₹ in Lakhs)
			Quarter Ended		Half Year Ended		Year Ended
. No.	Particulars	30 September	30 June	30 September	30 September	30 September	31 March
	i di ticului s	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited
		2021	2021	2020	2021	2020	2021
1	Revenue from operations						
	a) Sales/Income from operations	121707	113848	-	235555	-	67
	b) Other operating income	550	608	-	1158	-	
	Total revenue from operations	122257	114456	-	236713	-	68
2	Other income	696	598	-	1294	-	
3	Total income (1+2)	122953	115054	-	238007	-	6
4	Expenses						
	a) Cost of materials consumed	73705	60822	-	134527	-	3
	b) Purchases of stock-in-trade	4238	3387	-	7625	-	
	c) Changes in inventories of finished goods, stock-in-trade and work-in progress	(5720)	(6266)	-	(11986)	-	
	d) Employee benefits expense	7587	8100	-	15687	-	
	e) Finance costs	716	1281	-	1997	-	
	f) Depreciation and amortisation expense	3059	3162	-	6221	-	
	g) Other expenses:						
	- Power and fuel expense	10659	8353	-	19012	-	
	- Others	12256	11909	-	24165	-	
	Total expenses	106500	90748	-	197248	-	!
	Profit before share of loss of an associate and exceptional items (3-4)	16453	24306	-	40759	-	
	Share of loss of an associate	(2)	(1)	-	(3)	-	
	Profit before exceptional items and tax (5+6)	16451	24305	-	40756	-	
	Exceptional items	-	-	-	-	-	
	Profit before tax (7-8)	16451	24305	-	40756	-	
D [Tax expense						
	- Current tax	2900	4370	-	7270	-	
	- Deferred tax charge	2472	3109	-	5581	-	
ι	Net profit for the period (9-10)	11079	16826	-	27905	-	
2	Other comprehensive income (OCI)						
	i) a) Items that will not be reclassified to profit or loss	8487	236	-	8723	-	
	b) Income tax relating to items that will not be reclassified to profit or loss	101	(11)	-	90	-	
	ii) a) Items that will be reclassified to profit or loss	(44)	72	-	28	-	
	b) Income tax relating to items that will be reclassified to profit or loss	_	-	-	-	-	
3	Total comprehensive income for the period (11+12)	19623	17123	-	36746	-	
-	Net profit attributable to:						
	Owners of the Company	11079	16826	-	27905	-	
	Non-controlling interests	-	-	-	-	-	
	Other comprehensive income attributable to:						
	Owners of the Company	8544	297	-	8841	-	
	Non-controlling interests	-	-	-	-	-	
ŀ	Total comprehensive income attributable to:						
	Owners of the Company	19623	17123	-	36746	-	
	Non-controlling interests	-	-	-	-	-	
	.						
4	Earnings per share of ₹ 1 each (not annualised)						
	Basic (₹)	6.97	10.58	-	17.55	-	
	Diluted (₹)	6.97	10.58	-	17.55	-	
5	Paid-up equity share capital (face value per share ₹ 1)	1590	1590	5	1590	5	
6	Reserves excluding revaluation reserves (other equity)				225123	(17)	19
	See accompanying notes to the Consolidated Unaudited Financial Results	1			1		



		As at	(₹ in Lakh As at	
Sr. No.	Porticulare		31 March	
51. 190.	Particulars	30 September		
		(Unaudited)	(Audited)	
		2021	2021	
А	ASSETS			
1.	Non-current assets			
	Property, plant and equipment	173231	1744	
	Capital work-in-progress	9262	63	
	Intangible assets	1012	11	
	Intangible assets under development	321	1	
	Right-of-use assets	4986	49	
	Investments accounted for using the equity method	213	2	
	Financial assets:			
	Investments	345	48	
	Loans	49		
	Other financial assets	360	3	
	Deferred tax assets (net)	1478	12	
	Income-tax assets (net)	508	3	
	Other non-current assets	1691	14	
	Total non-current assets	193456	1954	
		199490	1954	
2.	Current assets			
	Inventories	76551	609	
	Financial assets:			
	Trade receivables	59344	471	
	Cash and cash equivalents	5064	73	
	Other bank balances	1966	43	
	Loans	52		
	Other financial assets	7614	67	
	Income tax assets (net)	3	-	
	Other current assets	17707	158	
	Total current assets	168301	1423	
	Total assets	361757	3378	
в	EQUITY AND LIABILITIES			
1.	Equity			
	Equity share capital	1590	15	
	Other equity	225123	1907	
	Total equity attributable to equity holders	226713	1922	
2.	Liabilities Non-current liabilities			
	Financial liabilities:			
	Borrowings	18419	455	
	Lease liabilities	801	455	
	Provisions	7029	69	
	Deferred tax liabilities (net)	8519	27	
	Total non-current liabilities	34768	561	
	Current liabilities			
	Financial liabilities:			
	Borrowings	7850	89	
	Lease liabilities	242		
	Trade payables	- 12		
	Total outstanding dues of micro enterprises and small enterprises	1119	1	
	Total outstanding dues of creditors other than micro enterprises and small enterprises	77300	680	
	Other financial liabilities	4310	6	
	Other current liabilities	3212	2	
	Provisions	1690 4553	12	
	Current tax liabilities (net) Total current liabilities		90/	
	rotar current lidbilities	100276	894	



Jubilant Ingrevia Limited Note 1: Statement of Consolidated Unaudited Cash Flows

	Half Year	(₹ in lakh:
Particulars	30 September	30 September
	(Unaudited)	(Unaudited)
	2021	2020
A. Cash flows from operating activities		
Profit before tax	40756	-
Adjustments:		
Depreciation and amortisation expense	6221	-
oss on sale/ disposal/ discard of property, plant and equipment (net)	527	-
Finance costs	1997	-
Share-based payment expense	55	-
Unrealised foreign exchange loss (net)	268	-
Interest income	(71)	-
Share of loss of an associate	3	-
	9000	-
Operating cash flows before working capital changes	49756	-
Increase in trade receivables, loans, other financial assets and other assets	(15320)	-
Increase in inventories	(15676)	-
Increase in trade payables, other financial liabilities, other liabilities and provisions	8724	-
Cash generated from operations	27484	-
Income tax paid (net of refund)	(3526)	-
Net cash generated from operating activities	23958	-
B. Cash flows from investing activities		
Purchase of property, plant and equipment, other intangible assets		
(including capital work-in-progress and intangible assets under development)	(9495)	-
Proceeds from sale of property, plant and equipment	138	-
Proceeds from sale of investments	13421	-
Movement in other bank balances	2311	-
Interest received	76	-
Net cash generated from investing activities	6451	-
C. Cash flows from financing activities		
Acquisition of shares by employee welfare trust	(1826)	
Repayment of long-term borrowings	(32969)	-
Payment of principal balances of lease liabilities	(158)	-
Proceeds from short-term borrowings (net)	4500	-
Dividend paid	(551)	
Finance costs paid (including interest on lease liabilities)	(2076)	-
Net cash used in financing activities	(33080)	-
	(55666)	
D. Effect of exchange rate changes	401	-
Net decrease in cash and cash equivalents (A+B+C+D)	(2270)	_
Add: cash and cash equivalents at the beginning of the period	7334	-
Cash and cash equivalents at the end of the period	7334 5064	



Note2: Consolidated Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Half Year Ended 30 September 2021

							(₹ in Lakhs)
			Quarter Ende	d	Half Yea	r Ended	Year Ended
C., N	Dentitudent	30 September	30 June	30 September	30 September	30 September	31 March
Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2021	2021	2020	2021	2020	2021
1	Segment revenue						
	a. Speciality Chemicals	39170	38756	-	77926		25957
	b. Nutrition & Health Solutions	17880	16708	-	34588	-	12800
	c. Life Science Chemicals	77899	71017	-	148916	-	35946
	Total	134949	126481		261430		74703
	Less : Inter segment revenue	12692	12025		24717	-	6290
	Total revenue from operations	122257	114456		236713		68413
	a. Speciality Chemicals	29509	30465	-	59974	-	20827
	b. Nutrition & Health Solutions	17880	16708	-	34588	-	12800
	c. Life Science Chemicals	74868	67283	-	142151	-	34786
	Total	122257	114456		236713		68413
2	Segment results (profit before tax, exceptional items and interest from each segment)						
	a. Speciality Chemicals	5472	6702	-	12174	-	3477
	b. Nutrition & Health Solutions	3156	2319	-	5475	-	1955
	c. Life Science Chemicals	9226	17308	-	26534	-	4560
	Total	17854	26329		44183		9992
	Less: i. Interest (finance costs)	716	1281	-	1997	-	733
	ii. Exceptional items and un-allocable expenditure (net of un-allocable income)	687	743	-	1430		1520
	Profit before tax	16451	24305		40756		7739
3	Segment assets						
	a. Speciality Chemicals	164397	168740	-	164397	-	155357
	b. Nutrition & Health Solutions	46883	43126	-	46883	-	44160
	c. Life Science Chemicals	136689	141672	-	136689		120265
	d. Unallocable corporate assets	13788	14698	5	13788	5	18070
	Total segment assets	361757	368236	5	361757	5	337852
4	Segment liabilities						
	a. Speciality Chemicals	23720	29039	-	23720	-	33180
	b. Nutrition & Health Solutions	7792	7719	-	7792	-	7215
	c. Life Science Chemicals	63880	68065	-	63880	-	46601
	d. Unallocable corporate liabilities	39652	55800	17	39652	17	58562
	Total segment liabilities	135044	160623	17	135044	17	145558



Note3: Additional disclosure as per Regulation 52 (4) and 54 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Consolidated)

		Quarter Ended			Half Yea	Year Ended	
		30 September	30 June	30 September	30 September	30 September	31 March
Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2021	2021	2020	2021	2020	2021##
1	Debt service coverage ratio (in times)#	12.97	8.60	-	8.00	-	5.6
	Definition: EBITDA/{finance costs + scheduled principal repayments (excluding prepayments)						
	during the period for long-term debts}						
	{EBITDA: Profit before tax + depreciation and amortisation expense + finance costs + exceptional						
	items}						
2	Interest service coverage ratio (in times)	28.27	22.44	-	24.53	-	16.3
	Definition: EBITDA/finance costs						
3	Bad debts to account receivable ratio (%)#	0.08%	-	-	0.09%	-	0.1
	Definition: Bad debts/average of opening and closing trade receivables						
	{Bad debts: Impairment balance as per statements of profit and loss}						
	{Accounts receivables: Trade receivables as per balance sheet}						
4	Debtors turnover (in times)#	2.07	2.17		4.45	-	1.:
	Definition: Revenue from operations/average of opening and closing trade receivables						
5	Inventory turnover (in times)#	0.91	0.81	-	1.89	-	0.5
	Definition: Cost of goods sold/average of opening and closing inventories						
6	Operating margin (%)	13.47%	21.83%	-	17.52%	-	12.0
	Definition: Operating profit/revenue from operations						
	{Operating profit: Operating Revenue - cost of goods sold - operating Expenses - depreciation and						
	amortisation expense}						
	{Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in						
	inventories of finished goods, stock-in-trade and work-in-progress}						
	{Operating Expenses: Employee benefits expense + other expenses}						
7	Net profit margin (%)	9.01%	14.62%	-	11.72%	-	7.92
	Definition: Net profit for the period/total income						
8	Paid-up debt capital (In ₹ Lakhs)	10000			10000		1000
•	Definition: Secured Rated Listed Redeemable Non-Convertible Debentures (Gross of debt initiation						100
	cost)						
_	· ·						
9	Net worth (In 🕊 Lakhs)	226713			226713		1922
10	Debt equity ratio (in times)	0.09			0.09		0.
	Definition: Net debts/net worth						
	{Net debts: Long term borrowings (including current maturities and gross of transaction costs) +						
	short term borrowings - cash and cash equivalents - other bank balances}						
11	Current ratio (in times)	1.68			1.68		1.
	Definition: Current assets/current liabilities						
12	Long term debt to working capital (in times)	0.27			0.27		0.
	Definition: Long term debt/working capital						
	[Long term debt: Long term borrowings (including current maturities and gross of transaction						
	costs}						
	{working capital: Current assets - current liabilities}						
13	Current liability ratio (in times)	0.74			0.74		0.
	Definition: Current liabilities/total liabilities						
14	Total debts to total assets (in times)	0.07			0.07		0.1
	Definition: Total debts/total assets						
	{Total debts: Long term borrowings (including current maturities and gross of transaction costs +						
	short term borrowings}						
15	Fixed assets coverage ratio (in times)	10.63			10.63		4.
	Definition: Total assets secured by a first pari-passu charge / indebtedness secured by or agreed to	20.05			10.05		
	be secured by first charge over fixed assets (i.e. aggregate external borrowing)						

Figures for the year ended 31 March 2021 are not comparable as it represents only two months of operations of Life Science Ingredients business from 1 February 2021 to 31 March 2021 (refer note 10 for further details).



- 4. The Group has considered the possible effects that may result from the Covid-19 pandemic, on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions, the Group has, as at the date of approval of these consolidated financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the Group. On the basis of evaluation and current indicators of future economic conditions, the Group expects to recover the carrying amounts of these assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The Group will continue to monitor any material changes to future economic conditions.
- 5. Pursuant to the Composite Scheme, the Life Science Ingredients business ("LSI business") of Jubilant Pharmova Limited got demerged into the Holding Company w.e.f. 1 February 2021, accordingly the consolidated financial results of the Group for quarter and year ended 31 March 2021 includes only two months of operations of LSI business from 1 February 2021 to 31 March 2021. Therefore, in order to present the actual scale of operation of the LSI business, the management has presented, in addition to, the consolidated financial results of the Group, the following financial information which has been derived/extracted from the discontinued operations disclosure in the financial results of the transferor company, Jubilant Pharmova Limited for respective periods presented, which has not been separately subjected to audit or review and has been presented as 'unaudited' supplementary information:

			(₹ in Lakhs
	Quarter Ended	Half Year Ended	Year Ended
	30 September	30 September	31 March
Particulars	(Unaudited)	(Unaudited)	(Unaudited)
	2020	2020	2021
	(3 months)	(6 months)	(10 months)
i) Total revenue from operations	78354	152039	280698
ii) Other income	383	805	1220
iii) Total income	78737	152844	281918
iv) Total expenses	69538	136796	247825
v) Profit before tax	9199	16048	34093
vi) Tax expenses	1477	3064	7918
vii) Net profit for the period	7722	12984	26175

- 6. On 8 October 2021, the Holding Company has entered into Share Purchase, Subscription and Shareholder's Agreement with AMP Energy C&I Private Limited and AMP Energy Green Fifteen Private Limited for acquisition of 26.60% stake of AMP Energy Green Fifteen Private Limited for putting up the solar power plant with capacity of 15.5 MW for Captive Power Consumption.
- 7. During the quarter ended 30 September 2021, the Holding Company has granted 41867 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Holding Company.
- During the quarter ended 30 September 2021, Jubilant Life Sciences International Pte. Limited, Singapore, a wholly owned subsidiary of the Holding Company has divested its entire 10% stake, consisting of 5,40,463 shares, held in Safe Foods Corporation on 21 September 2021 for a consideration of USD 18.2 million (`13421 Lakhs), pursuant to approval of the plan of merger between Safe Food Corporation and Packers Sanitation Services Inc. Limited.
- 9. The Secured Rated Listed Redeemable Non-Convertible Debentures (NCDs) aggregating to ₹10000 lakhs outstanding as at 30 September 2021 are secured by a first pari-passu charge created by way of mortgage on certain immovable assets and hypothecation on entire movable property, plant and equipment, both present and future, of the Company. On 6 May 2021, CRISIL Limited has assigned the rating of "CRISIL AA/ Stable" to the said NCDs. The asset cover thereof based on agreed methodology exceeds 100% of the outstanding principal amount of the said NCDs.

Details of due dates for payment of interest and repayment of principal of NCDs are as follows:

Particulars	Previou	is Due Date	Next Due Date	
	Principal	Interest	Principal	Interest
1000 – 7.90% Non - Convertible Debentures of ₹ 10 lakhs each	-	2 June 2021*	2 June 2023	2 June 2022

*Interest due on 2 June 2021 has been paid on the due date

- 10. The figures for the quarter ended 30 September 2021 and half year ended 30 September 2021 are not comparable with previous periods since the figures for quarter and half year ended 30 September 2020 is without the results of LSI business and the figures for the year ended 31 March 2021 include results of demerged LSI business from Jubilant Pharmova Limited for two months, from the effective date of demerger i.e., 1 February 2021 till 31 March 2021. Further, figures for quarter and half year ended 30 September 2020 have not been subjected to audit or review by the Statutory Auditors as they are for the period before listing of the Holding Company i.e. 19 March 2021.
- 11. Previous period figures have been regrouped /reclassified to conform to the current period's classification.
- 12. The above consolidated unaudited financial results were subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 19 October 2021. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on consolidated financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.



Place : Noida Date : 19 October 2021 Rajesh Kumar Srivastava CEO & Managing Director

For Jubilant Ingrevia Limited RAJESH KUMAR SRIVASTAVA SRIVASTAVA



Jubilant Ingrevia Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 www.jubilantingrevia.com

PRESS RELEASE

Noida, Tuesday, October 19, 2021

JUBILANT INGREVIA – Q2 & H1'FY22 RESULTS*

						<u>(Rs Crs)</u>
Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)	H1'FY21 ²	H1'FY22	YoY (%)
Total Revenue from Operations	784	1,223	56%	1,520	2,367	56%
EBITDA	140	202	44%	267	490	83%
EBITDA Margin	17.9%	16.5%		18%	21%	
Profit After Tax	77	111	43%	130	279	115%
PAT Margin	9.9%	9.1%		9%	12%	
EPS - Face Value Re. 1 (Rs.)	4.8	7.0	43%	8.2	17.6	115%

*Financial numbers for comparative periods are presented on Pro-forma basis to reflect continuing operations pre and post demerger as explained in Note 2 in the disclaimer.

The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter & Half Year ended September 30th, 2021.

Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman, Jubilant Ingrevia Limited said:

"With immense pleasure, I would like to announce that we have delivered yet another strong financial performance in Q2'FY22 and reported our highest ever revenue during the Quarter & Half Year ended 30th Sept'21.

Supply disruptions from China is coming to our advantage, due to which we are witnessing strong demand in most of our products and that is giving us an opportunity to increase our share with the global customers, while on the sourcing side we are having negligible dependence on China. We are finding unprecedented increase in almost all the input raw materials, fuels like Coal & Gas & Logistic cost, however our business team is confident to pass on the incremental costs by working closely with customers

In our Specialty Chemicals segment we witnessed strong growth across the products led by growing demand from Pharmaceutical and Agrochemical customers. In Nutrition & Health Solution the demand of Vitamin B3 has been stable, and prices started to increase in Vitamin B3. We continue to work to improve our market share in niche segments like food and cosmetics. In Life Science Chemical Segment, we witnessed healthy demand from Pharmaceutical and Agrochemical customers resulting in volume growth in all the products.

I am happy to announce that we reduced the net debt further by Rs 193 Crore during Q2'FY22.

Looking Ahead we are excited with the growth opportunities in our businesses and we are fully committed to realize them. We have developed strong product pipeline using in-house R&D, our technical expertise into various chemistry platforms and long-standing relationship with global Pharmaceutical & Agrochemical customers including Innovators. We are prioritizing and investing in several growth capex in next 2-3 years to launch these products to achieve our growth target of doubling the revenue by FY'26 from the base of FY'21."



Q2'FY22 Highlights

A. Consolidated

Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)
Revenue			
Speciality Chemicals	252	295	17%
Nutrition & Health Solutions	125	179	43%
Life Science Chemicals	406	749	84%
Total Revenue from Operations	784	1,223	56%
Reported EBITDA	140	202	44%
Speciality Chemicals	71	71	0%
Nutrition & Health Solutions	28	35	23%
Life Science Chemicals	40	103	160%
Unallocated Corporate (Expenses)/Income	2	-7	-
PAT	77	111	43%
EPS	4.8	7.0	43%
Reported EBITDA Margins	17.9%	16.5%	
Speciality Chemicals	28.1%	24.1%	
Nutrition & Health Solutions	22.6%	19.5%	
Life Science Chemicals	9.7%	13.8%	
Net Margin	9.9%	9.1%	

- Revenue grew by 56% on YoY basis, driven by robust growth in volume and prices.
- Speciality Chemicals revenue grew by 17% YoY driven by volume growth across product segments.
- Nutrition and Health Solutions revenue grew by 43% YoY driven by higher volumes and growth in Niacinamide price.
- Life Sciences Chemical revenue grew by 84% YoY, driven by higher prices on account of favorable market conditions and passing-on of higher input cost of acetic acid.
- EBITDA at Rs 202 Crore, grew by 44%, on account of strong performance of Life Sciences chemical segment led by favorable market conditions and volume growth in Nutrition and Health Solution.
- PAT grew by 43% YoY driven by growth in EBITDA, added by reduction in finance cost through reduction in Gross debt and optimization of Interest rates.
- ROCE in H1'FY22 improved to 33.2% against 20.2% in FY21
- ROE in H1'FY22 improved to 26.6% over 16.4% in FY21

Segment Wise Analysis

B. Speciality Chemicals

Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)
Revenue	252	295	17%
Reported EBITDA	71	71	0%
Reported EBITDA Margin (%)	28.1%	24.1%	

• Specialty Chemicals revenue grew by 17% on YoY basis driven by higher volume across product segments

- North America revenue grew significantly; percentage share to total revenue increased to 11% from 9%.
- Domestic Sales for International consumption percentage share to total revenue grew from 6% to 12 %
- Agrochemical grew as percentage share to total revenue increased to 25% from 21%.
- Consumer as percentage share to total revenue increased to 9% from 7%.
- EBITDA remained flat and EBITDA Margin declined at 24.1% vs 28.1% in Q2'FY21, due to volatility in prices of input costs.



C. Nutrition & Health Solutions

Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)
Revenue	125	179	43%
Reported EBITDA	28	35	23%
Reported EBITDA Margin (%)	22.6%	19.5%	

- Nutrition and Health Solutions revenue grew by 43% on YoY basis.
 - Growth was driven by prices and growth in Niacinamide volume.
 - Animal Nutrition and Health solution business growth was led by higher volumes of Choline Chloride and specialty products.
- Consumption in EU and contribution in sales has gone up from 20% to 28 % and in North America from 12% to 23%,
- Feed volumes grew by 34% and Food by more than 100%
- EBITDA grew by 23% on YoY basis. EBIDTA Margin stood at 19.5% vs 22.6% in Q2'FY21, EBITDA margin was lower by 3.1% on account of continuing increase in input costs and along with discontinuation of export benefit (MEIS).

D. Life Science Chemicals Segment

Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)
Revenue	406	749	84%
Reported EBITDA	40	103	160%
Reported EBITDA Margin (%)	9.7%	13.8%	

- Life Sciences Chemicals revenue grew by 84% on YoY basis
- Life Sciences Chemical revenue growth was driven by higher prices across products and higher volume of Acetic Anhydride.
- Prices improvement was mainly on account of favorable market condition driven by disruption in European and China market driven by force majeure by key supplier of Acetyl products.
- Consumption in domestic sales for export has gone up significantly and its contribution percentage to revenue increased from 18% to 23%.
- EBITDA Margin stood at 13.8% compared to 9.7% in Q2'FY21. Growth in EBITDA margin was driven by
 - Improved product contribution driven by favourable market condition.



H1'FY22 Highlights

E. Consolidated

Particulars ¹	H1'FY21 ²	H1'FY22	YoY (%)
Revenue			
Speciality Chemicals	509	600	18%
Nutrition & Health Solutions	274	346	26%
Life Science Chemicals	737	1,422	93%
Total Revenue from Operations	1,520	2,367	56%
Reported EBITDA	267	490	83%
Speciality Chemicals	140	155	11%
Nutrition & Health Solutions	60	61	3%
Life Science Chemicals	63	287	353%
Unallocated Corporate (Expenses)/Income	5	-14	-
PAT	130	279	115%
EPS	8.2	17.6	115%
Reported EBITDA Margins	17.6%	20.7%	
Speciality Chemicals	27.4%	25.9%	
Nutrition & Health Solutions	21.8%	17.7%	
Life Science Chemicals	8.6%	20.2%	
Net Margin	8.5%	11.8%	

• Revenue grew by 56% on YoY basis, driven by robust growth in volume and prices.

- Speciality Chemicals revenue grew by 18% YoY driven by volume growth across product segments.
- Nutrition and Health Solutions revenue grew by 26% YoY driven by higher volumes and growth in Niacinamide price
- Life Sciences Chemical revenue grew by 93% YoY, driven by higher prices on account of favorable market conditions and pass-on of higher input cost of acetic acid
- EBITDA at Rs. 490 Crore, grew by 83% on account of strong performance of Life Sciences chemical segment led by favorable market conditions supported by Speciality Chemicals.
- PAT grew by 115% YoY driven by growth in EBITDA, aided by reduction in finance cost on account of reduction in Debt and optimization of Interest rates.
- ROCE in H1'FY22 improved to 33.2% against 20.2% in FY21
- ROE in H1'FY22 improved to 26.6% over 16.4% in FY21

Segment Wise Analysis

F. Speciality Chemicals

Particulars ¹	H1'FY21 ²	H1'FY22	YoY (%)
Revenue	509	600	18%
Reported EBITDA	140	155	11%
Reported EBITDA Margin (%)	27.4%	25.9%	

• Specialty Chemicals revenue grew by 18% on YoY basis driven by higher volume across product segments

• North America revenue grew significantly; percentage share to total revenue increased to 10% from 7%.

- Domestic Sales for International consumption percentage share to total revenue grew from 6% to 12%.
- Nutrition grew as percentage share to total revenue increased to 8% from 5%.
- Consumer as percentage share to total revenue increased to 10% from 8%.
- EBITDA grew by 11% YoY. EBITDA Margin declined at 25.9% vs 27.4% in H1'FY21, due to higher raw material prices.



G. Nutrition & Health Solutions

Particulars ¹	H1'FY21 ²	H1'FY22	YoY (%)
Revenue	274	346	26%
Reported EBITDA	60	61	3%
Reported EBITDA Margin (%)	21.8%	17.7%	

- Nutrition and Health Solutions revenue grew by 26% on YoY basis.
 - Growth was driven by prices and growth in Niacinamide volume.
 - Growth in Animal Nutrition and Health Solutions was led by volume growth in Choline Chloride and specialty products.
- Consumption in EU and North America has gone up significantly.
- Feed and Food demand has gone up on YoY basis in higher double digit
- EBITDA grew by 3% on YoY basis. EBIDTA Margin stood at 17.7% vs 21.8% in H1'FY21, EBITDA margin lower by 4.0% mainly on account of continuing increase in input costs and along with discontinuation of export benefit (MEIS).

H. Life Science Chemicals Segment

Particulars ¹	H1'FY21 ²	H1'FY22	YoY (%)
Revenue	737	1,422	93%
Reported EBITDA	63	287	353%
Reported EBITDA Margin (%)	8.6%	20.2%	

Life Sciences Chemicals revenue grew by 93% on YoY basis

- Life Sciences Chemical revenue growth was driven by higher prices and volume growth in Acetic Anhydride.
- Prices improvement was mainly on account of favorable market condition
- Consumption in domestic sales for export has gone up and its contribution percentage to revenue increased to 22% from 18% in H1'FY21
- EBITDA Margin stood at 20.2% compared to 8.6% in H1'FY21. Growth in EBITDA margin was driven by
 - Improved product contribution driven by favorable market condition and Acetic Acid stock led benefit due to increase in prices.
 - Acetic Acid stock led benefit due to increase in prices.

I. Business Outlook

- Demand of most of our Products is expected to remain strong in H2. Though input costs are increasing our business teams are confident to pass on the incremental costs by working closely with customers
- We will continue to make efforts to deleverage the Balance Sheet and reduce the Debt without compromising on growth.
- Progress of ongoing Diketene Capex is as per schedule, and is expected to be commissioned during the Quarter Jan to March 2022.
- Further during the year so far we have committed investment worth Rs. 450 Crore for following growth capex. At peak capacity these investments are expected to generate additional annual revenue of Rs. 900-1,000 Crore at prevailing prices
 - CDMO GMP Facility at Bharuch. (Expected to be in operation during the quarter April to June 2022)
 - Three Multi-Purpose plants of Speciality Chemicals. (Expected to be in operation during the quarter July to Sep 2022)
 - Food Grade Acetic Acid. (Expected to be in operation during the quarter April to June 2022)
 - Acetic Anhydride Plant. (Expected to be in operation during the quarter Jan to Mar 2023)
 - Agro Actives Phase-1. (Expected to be in operation during the quarter Jan to March 2023)
- Our expected capex cash outflow for the year will be in the range of Rs 350 crore.



Income Statement – Q2 & H1'FY22

Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)	H1'FY21 ²	H1'FY22	YoY (%)
Total Revenue from Operations	784	1,223	56%	1,520	2,367	56%
Speciality Chemicals	252	295	17%	509	600	18%
Nutrition & Health Solutions	125	179	43%	274	346	26%
Life Science Chemicals	406	749	84%	737	1,422	93%
Total Expenditure	647	1,027	59%	1,261	1890	50%
Other Income	4	7		8	13	
Segment EBITDA						
Speciality Chemicals	71	71	0%	140	155	11%
Nutrition & Health Solutions	28	35	23%	60	61	3%
Life Science Chemicals	40	103	160%	63	287	353%
Unallocated Corporate (Expenses)/Income	2	-7	(541%)	5	-14	(390%)
Reported EBITDA	140	202	44%	267	490	83%
Depreciation and Amortization	31	31	(1%)	61	62	1%
Finance Cost	17	7.2	(59%)	46	20	(56%)
Profit before Tax (After Exceptional Items)	92	165	79%	160	408	154%
Tax Expenses (Net)	15	54	264%	31	129	319%
PAT	77	111	43%	130	279	115%
EPS - Face Value Re. 1 (Rs.)	4.8	7.0	43%	8.2	17.6	115%
Segment EBITDA Margins						
Speciality Chemicals	28.1%	24.1%		27.4%	25.9%	
Nutrition & Health Solutions	22.6%	19.5%		21.8%	17.7%	
Life Science Chemicals	9.7%	13.8%		8.6%	20.2%	
Reported EBITDA Margin	17.9%	16.5%		17.6%	20.7%	
Net Margin	9.9%	9.1%		8.5%	11.8%	

1. All figures are in Rs Crore unless otherwise stated

Q2'FY21 and H1'21 is derived from discontinued operation of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
 EPS has been computed on combined profits assuming existence of share capital for full year.

Earnings Call details

The company will host earnings call at 5.00 PM IST on

Participants can dial-in on the numbers below Primary Number: + 91 22 6280 1141 / + 91 22 7115 8042 Local Access Number: +91-7045671221 (Available all over India) Toll Free Numbers: USA: 1866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448

Replay: October 19 to October 26, 2021 Dial-in: +91 22 7194 5757/ +91 22 66635757 Playback ID: 00999#



About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The company has 2,100 employees and serves more than 1,400 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

Jubilant Ingrevia is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers.

For more information, please visit: <u>www.jubilantingrevia.com</u>.

For more information, please contact:

For Investors

Pavleen Taneja Ph: +91-120 436 1002 | 21 E-mail: pavleen.taneja@jubl.com Siddharth Rangnekar CDR India Ph: +91 22 6645 1209 E-mail: siddharth@cdr-india.com

For Media

Sudhakar Safaya Ph: +91-120 436 1034 E-mail: sudhakar.safaya@jubl.com Clayton Dsouza Madison Public Relations E-mail: clayton.dsouza@madisonpr.in Phone number: +91 9930011602

Disclaimer:

Note 1

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Note 2:

Effective 1st February 2021, Life Science Ingredients business of Jubilant Pharmova Limited (earlier Jubilant Life Sciences Limited) demerged to Jubilant Ingrevia Limited and post demerger the consolidated financial results of the Jubilant Ingrevia Limited for the quarter and the year ended 31 March 2021 comprised results only for two months of operations, starting from 1st February 2021.


To provide the comprehensive picture of the operations of the Company on continuing basis the results for previous periods has been presented on Proforma basis by using relevant portion of the published results of LSI Segment - Jubilant Pharmova Limited on Pro-forma basis as Under:

- Results of Q1'FY21, Q2 & H1'FY22 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Proforma basis
- As explained in the Financial Results presentation deck for Q4'FY 21 we had earlier presented results for fully year FY 21 on Pro-forma basis by combining the results from 01 April 2020 to 31 January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited and results for Q4'FY21 on Pro-forma basis by combining the results for January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited
- EPS for previous periods has been computed assuming existence of share capital throughout the period.
- ROCE & ROE for H1'FY22 is calculated on the basis of extrapolation of six months' performance during FY22.



Financial Results

Quarter & Half Year Ended 30th September, 2021



Disclaimer UBILANT

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Effective 1st February 2021, Life Science Ingredients business of Jubilant Phormova Limited (earlier Jubilant Life Sciences Limited) demerged to Jubilant Ingrevia Limited and post demerger the consolidated financial results of the Jubilant Ingrevia Limited for the quarter and the year ended 31 March 2021 comprised results only for two months of operations, starting from 1st February 2021.

To provide the comprehensive picture of the operations of the Company on continuing basis the results for previous periods has been presented on Pro-forma basis by using relevant portion of the published results of LSI Segment - Jubilant Pharmova Limited on Pro-forma basis as Under :

- Results for Q1'FY21, Q2'FY21 and H1'FY21 has been derived on Pro-forma basis from the reported discontinued operations results for LSI segment of Jubilant Pharmova Limited.
- As explained in the Financial Results presentation deck for Q4'FY21 we had earlier presented results for fully year FY 21 on Pro-forma basis by combining the results from 01 April 2020 to 31 January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited and results for Q4'FY21 on Pro-forma basis by combining the results for January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited
- EPS for previous periods has been computed assuming existence of share capital throughout the period *NOTES:*
 - 1. The numbers for the quarter and Half Year have been reclassified and regrouped wherever necessary
 - 2. Closing Exchange Rate for USD 1 at Rs 73.11 as on March 31, 2021 and Rs 74.23 as on September 30, 2021



Date : October 19, 2021 Time : 05:00 pm IST

Conference Dial-In Numbers	
	+ 91 22 6280 1141
Universal Access:	+ 91 22 7115 8042
	USA: 1 866 746 2133
Toll Free Number:	UK: 0 808 101 1573
	Singapore: 800 101 2045
	Hong Kong: 800 964 448
	Available from October 19 to October 26, 2021
Replay Facility:	Dial in No.: +91 22 7194 5757 / +91 22 6663 5757
	Playback ID: 00999#

Chairmen's Message





"With immense pleasure, I would like to announce that we have delivered yet another strong financial performance in Q2'FY22 and reported our highest ever revenue during the Quarter & Half Year ended 30th Sept'21.

Supply disruptions from China is coming to our advantage, due to which we are witnessing strong demand in most of our products and that is giving us an opportunity to increase our share with the global customers, while on the sourcing side we are having negligible dependence on China. We are finding unprecedented increase in almost all the input raw materials, fuels like Coal & Gas & Logistic cost, however our business team is confident to pass on the incremental costs by working closely with customers

In our Specialty Chemicals segment we witnessed strong growth across the products led by growing demand from Pharmaceutical and Agrochemical customers. In Nutrition & Health Solution the demand of Vitamin B3 has been stable, and prices started to increase in Vitamin B3. We continue to work to improve our market share in niche segments like food and cosmetics. In Life Science Chemical Segment, we witnessed healthy demand from Pharmaceutical and Agrochemical customers resulting in volume growth in all the products.

I am happy to announce that we reduced the net debt further by Rs 193 Crore during Q2'FY22.

Looking ahead we are excited with the growth opportunities in our businesses and we are fully committed to realize them. We have developed strong product pipeline using in-house R&D, our technical expertise into various chemistry platforms and long-standing relationship with global Pharmaceutical & Agrochemical customers including Innovators. We are prioritizing and investing in several growth capex in next 2-3 years to launch these products to achieve our growth target of doubling the revenue by FY'26 from the base of FY'21."

Financial Highlights¹ : Key Financial Parameters






1. All figures are in Rs Crore unless otherwise stated

2. - Q2 & H1'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis

- EPS for previous periods has been computed on combined profits assuming existence of share capital for full period.

Jubilant Ingrevia: Business Segments & Integrated Operations








Q2'FY22 Results Analysis

Jubilant Ingrevia – Q2'FY22 Financial Highlights



Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)
Revenue			
Speciality Chemicals	252	295	17%
Nutrition & Health Solutions	125	179	43%
Life Science Chemicals	406	749	84%
Total Revenue from Operations	784	1,223	56%
Reported EBITDA	140	202	44%
Speciality Chemicals	71	71	0%
Nutrition & Health Solutions	28	35	23%
Life Science Chemicals	40	103	160%
Unallocated Corporate (Expenses)/Income	2	-7	-
РАТ	77	111	43%
EPS	4.8	7.0	43%
Reported EBITDA Margins	17.9%	16.5%	
Speciality Chemicals	28.1%	24.1%	
Nutrition & Health Solutions	22.6%	19.5%	
Life Science Chemicals	9.7%	13.8%	
Net Margin	9.9%	9.1%	

- Revenue grew by 56% on YoY basis, driven by robust growth in volume and prices.
- Speciality Chemicals revenue grew by 17% YoY driven by volume growth across product segments.
- Nutrition and Health Solutions revenue grew by 43% YoY driven by higher volumes and growth in Niacinamide price.
- Life Sciences Chemical revenue grew by 84% YoY, driven by higher prices on account of favorable market conditions and passing-on of higher input cost of acetic acid.
- EBITDA at Rs 202 Crore, grew by 44%, on account of strong performance of Life Sciences chemical segment led by favorable market conditions and volume growth in Nutrition and Health Solution.
- PAT grew by 43% YoY driven by growth in EBITDA, added by reduction in finance cost through reduction in Gross debt and optimization of Interest rates.
- ROCE in H1'FY22 improved to 33.2% against 20.2% in FY21
- ROE in H1'FY22 improved to 26.6% over 16.4% in FY21



1. All figures are in Rs Crore unless otherwise stated

- 2. Q2 & H1'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
- EPS for previous periods has been computed on combined profits assuming existence of share capital for full period.

3. ROCE & ROE for H1'FY22 is calculated on the basis of extrapolation of six months performance during FY22.

Speciality Chemicals- Key Highlights Q2'FY22



- China Industry shutdown led by pollution control measures and energy consumption targets is driving global volatility and higher input prices in almost all key raw material & Fuel prices and also affecting availability.
- We are focusing on sourcing and availability of all inputs to ensure supply continuity for customers.
 Our input costs relating to raw material, utility and logistic are increasing however business is confident to pass on the incremental costs by working closely with customers


MARKET & BUSINESS HIGHLIGHTS

- International Logistics situation remain challenging on the shipping front and the logistics Issues in respect of container movement and vessel availability is leading to higher freight costs and longer delivery timelines.
- ✓ We handle large volume transportation and with our long standing relationship with shipping and transport companies we are successfully achieving timely delivery to our customers
- Overall demand continues to be strong. Domestic demand continues to improve due to shift of some of the Pharmaceutical & Agrochemical end products customers from China to India leading to improved capacity utilization.
- We are finding positive traction from both domestic as well as international customers on new Product enquiries as well as increased market share from existing customers

Speciality Chemicals Segment Highlights – Q2'FY22



Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)
Revenue	252	295	17%
Reported EBITDA	71	71	0%
Reported EBITDA Margin (%)	28.1%	24.1%	



*Industrial include Paints & Coatings, Print & Packaging, Solvents etc. **Consumer include Personal Care, Fragrances etc.

- Specialty Chemicals revenue grew by 17% on YoY basis driven by higher volume across product segments
- North America revenue grew significantly, percentage share to total revenue increased to 9% from 11%.
- Domestic Sales for International consumption percentage share to total revenue grew from 6% to 12 %
- Agrochemical grew as percentage share to total revenue increased to 25% from 21%.
- Consumer as percentage share to total revenue increased to 9% from 7%.

EBITDA:

 EBITDA remained flat and EBITDA Margin declined at 24.1% vs 28.1% in Q2'FY21, due to volatility in prices of input costs.

- 1. All figures are in Rs Crore unless otherwise stated
- 2. Q2 & H1'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
- 3. Specialty Chemicals Segment comprises Specialty Ingredients, Fine Chemicals, Crop Protection Chemicals & CDMO




	 During the quarter, there has been reduction of African Swine Fever in China which has resulted into overall demand improvement of Vitamin B3 (Niacinamide & Niacin).
MARKET & BUSINESS HIGHLIGHTS	 We were in a position to place higher volume both QoQ as well as YoY basis. We continue to focus on improving our market share in niche segments like Food &
	 Cosmetics and also focusing to enhance our market share in North America markets Demand in Animal Nutrition Segment remain stable driven by recovery in Poultry, Aquaculture
	 Animal Nutrition business continues making efforts to increase share of speciality premixes through various initiatives ✓ Raw material, utility and logistics costs, which increased sharply during the quarter, were
	passed on partially

Nutrition & Health Solutions Segment Highlights – Q2'FY22



Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)
Revenue	125	179	43%
Reported EBITDA	28	35	23%
Reported EBITDA Margin (%)	22.6%	19.5%	



- 1. All figures are in Rs Crore unless otherwise stated
- 2. Q2 & H1'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
- 3. Nutrition & Health Solutions Segment comprises, Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, Human Nutrition & Health Solution

- Nutrition and Health Solutions revenue grew by 43% on YoY basis.
 - Growth was driven by prices and growth in Niacinamide volume.
 - Animal Nutrition and Health solution business growth was led by higher volumes of Choline Chloride and specialty products.
- Consumption in EU and contribution in sales has gone up from 20% to 28% and in North America from 12% to 23%,
- Feed volumes grew by 34% and Food by more than 100%
- EBITDA
- EBITDA grew by 23% on YoY basis. EBIDTA Margin stood at 19.5% vs 22.6% in Q2'FY21, EBITDA margin was lower by 3.1% on account of continuing increase in input costs and along with discontinuation of export benefit (MEIS).

Life Sciences Chemicals - Key Highlights Q2 FY'22




Life Sciences Chemical market condition remained favourable due to supply disruption in European and China market driven by force majeure by key supplier of Acetyl products. Though Acetic Acid price during end of quarter increased sharply however during the quarter it was lower in comparison to Q1-FY'22 Acetic Anhydride demand was stable during the quarter. ✓ We could place better volume of Acetic Anhydride during the quarter both on QoQ as well as on YoY basis. **MARKET &** ✓ Maintained domestic market leadership for Acetic Anhydride and increased market BUSINESS presence in Europe, Americas and Rest of the world. HIGHLIGHTS During beginning of quarter demand of Ethyl Acetate was lower which improved significantly during later part of the quarter. ✓ Due to better demand specially during later part of the quarter, we could place higher volume of Ethyl Acetate in India as well as in Europe on QoQ basis Specialty Ethanol market demand continued to be strong, which has resulted in higher volume YoY basis and stable on QoQ basis.

Life Science Chemicals Segment Highlights – Q2'FY22



Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)
Revenue	406	749	84%
Reported EBITDA	40	103	160%
Reported EBITDA Margin (%)	9.7%	13.8%	



- Life Sciences Chemicals revenue grew by 84% on YoY basis
 - Life Sciences Chemical revenue growth was driven by higher prices across products and higher volume of Acetic Anhydride.
 - Prices improvement was mainly on account of favorable market condition driven by disruption in European and China market driven by force majeure by key supplier of Acetyl products.
 - Consumption in domestic sales for export has gone up significantly and its contribution percentage to revenue increased from 18% to 23%.

<u>EBITDA</u>

- EBITDA Margin stood at 13.8% compared to 9.7% in Q2'FY21.
 Growth in EBITDA margin was driven by
 - Improved product contribution driven by favorable market condition

- 1. All figures are in Rs Crore unless otherwise stated
- 2. Q2 & H1'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
- 3. Life Science Chemicals Segment comprises, Life Science Ingredients and Speciality Ethanol



H1'FY22 Results Analysis

Jubilant Ingrevia – H1'FY22 Financial Highlights

.


•

٠



Particulars ¹	H1'FY21 ²	H1'FY22	YoY (%)
Revenue			
Speciality Chemicals	509	600	18%
Nutrition & Health Solutions	274	346	26%
Life Science Chemicals	737	1,422	93%
Total Revenue from Operations	1,520	2,367	56%
Reported EBITDA	267	490	83%
Speciality Chemicals	140	155	11%
Nutrition & Health Solutions	60	61	3%
Life Science Chemicals	63	287	353%
Unallocated Corporate (Expenses)/Income	5	-14	-
РАТ	130	279	115%
EPS	8.2	17.6	115%
Reported EBITDA Margins	17.6%	20.7%	
Speciality Chemicals	27.4%	25.9%	
Nutrition & Health Solutions	21.8%	17.7%	
Life Science Chemicals	8.6%	20.2%	
Net Margin	8.5%	11.8%	

- Revenue grew by 56% on YoY basis, driven by robust growth in volume and prices.
- Speciality Chemicals revenue grew by 18% YoY driven by volume growth across product segments.
- Nutrition and Health Solutions revenue grew by 26% YoY driven by higher volumes and growth in Niacinamide price
- Life Sciences Chemical revenue grew by 93% YoY, driven by higher prices on account of favorable market conditions and pass-on of higher input cost of acetic acid
- EBITDA at Rs 490 Crore, grew by 83% on account of strong performance of Life Sciences chemical segment led by favorable market conditions supported by Speciality Chemicals.
- PAT grew by 115% YoY driven by growth in EBITDA, aided by reduction in finance cost on account of reduction in Debt and optimization of Interest rates .
- ROCE in H1'FY22 improved to 33.2% against 20.2% in FY21
- ROE in H1'FY22 improved to 26.6% over 16.4% in FY21




- 1. All figures are in Rs Crore unless otherwise stated
- 2. Q2 & H1'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
 - EPS has been computed on combined profits assuming existence of share capital for full period.
- 3. ROCE & ROE for H1'FY22 is calculated on the basis of extrapolation of six months performance during FY22.

Speciality Chemicals Segment Highlights – H1'FY22



Particulars ¹	H1'FY21 ²	H1'FY22	YoY (%)
Revenue	509	600	18%
Reported EBITDA	140	155	11%
Reported EBITDA Margin (%)	27.4%	25.9%	



*Industrial include Paints & Coatings, Print & Packaging, Solvents etc. **Consumer include Personal Care, Fragrances etc.

- 1. All figures are in Rs Crore unless otherwise stated
- 2. Q2 & H1'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
- 3. Specialty Chemicals Segment comprises Specialty Ingredients, Fine Chemicals, Crop Protection Chemicals & CDMO


- Specialty Chemicals revenue grew by 18% on YoY basis driven by higher volume across product segments
- North America revenue grew significantly, percentage share to total revenue increased to 10% from 7%.
- Domestic Sales for International consumption percentage share to total revenue grew from 6% to 12 %
- Nutrition grew as percentage share to total revenue increased to 8% from 5%.
- Consumer as percentage share to total revenue increased to 10% from 8%.

EBITDA:

 EBITDA grew by 11% YoY. EBITDA Margin declined at 25.9% vs 27.4% in H1'FY21, due to higher raw material prices

Nutrition & Health Solutions Segment Highlights – H1'FY22

Particulars ¹	H1'FY21 ²	H1'FY22	YoY (%)
Revenue	274	346	26%
Reported EBITDA	60	61	3%
Reported EBITDA Margin (%)	21.8%	17.7%	



- 1. All figures are in Rs Crore unless otherwise stated
- Q2 & H1'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
- 3. Nutrition & Health Solutions Segment comprises, Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, Human Nutrition & Health Solution



- Nutrition and Health Solutions revenue grew by 26% on YoY basis.
 - Growth was driven by prices and growth in Niacinamide volume.
 - Growth in Animal Nutrition and Health Solutions was led by volume growth in Choline Chloride and specialty products.
- Consumption in EU and North America has gone up significantly.
- Feed and Food demand has gone up on YoY basis in higher double digit


EBITDA

 EBITDA grew by 3% on YoY basis. EBIDTA Margin stood at 17.7% vs 21.8% in H1'FY21, EBITDA margin lower by 4.0% mainly on account of continuing increase in input costs and along with discontinuation of export benefit (MEIS).

Life Science Chemicals Segment Highlights – H1'FY22



Particulars ¹	H1'FY21 ²	H1'FY22	YoY (%)
Revenue	737	1,422	93%
Reported EBITDA	63	287	353%
Reported EBITDA Margin (%)	8.6%	20.2%	



- Life Sciences Chemicals revenue grew by 93% on YoY basis
 - Life Sciences Chemical revenue growth was driven by higher prices and volume growth in Acetic Anhydride.
 - Prices improvement was mainly on account of favorable market condition
 - Consumption in domestic sales for export has gone up and its contribution percentage to revenue increased to 22% from 18% in H1'FY21

EBITDA

- EBITDA Margin stood at 20.2% compared to 8.6% in H1'FY21. Growth in EBITDA margin was driven by
 - Improved product contribution driven by favorable market condition and Acetic Acid stock led benefit due to increase in prices.
 - Acetic Acid stock led benefit due to increase in prices.

- 1. All figures are in Rs Crore unless otherwise stated
- 2. Q2 & H1'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis.
- 3. Life Science Chemicals Segment comprises, Life Science Ingredients and Speciality Ethanol


Particulars ¹	31-Mar-21	30-Jun-21	30-Sep-21
Long Term Borrowings	548	227	218
Short Term Borrowings	-	230	45
Total Gross Debt	548	457	263
Cash & Equivalent	117	70	70
Total Net Debt	431	386	193
QoQ change		-10%	-50%

- Gross Debt and Net Debt reduction of Rs 193 Crore in Q2'FY 22.
- Net Debt to EBITDA in Q2'FY22 stands at 0.2 times, from the earlier level of 0.5 times as on 30th June, 2021.
- Average blended interest rate for Q2'FY22 was 5.53%, against 7.25 % in Q2'FY21 and average Net Debt during Q2'FY22 was lower by Rs 238 Crore as compared to 31st March 2021.

^{1.} All figures are in Rs Crore unless otherwise stated

Balance Sheet – Key Parameters/Ratios (Pro-Forma²)





No of Days of Working Capital

1. All figures are in Rs Crore unless otherwise stated

2. FY21 is calculated from 10 month of discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months of Jubilant Ingrevia Limited

3. H1'FY22 is calculated on the basis of extrapolation of six months performance during FY22

Business outlook



- Demand of most of our Products is expected to remain strong in H2. Though input costs are increasing our business teams are confident to pass on the incremental costs by working closely with customers
- We will continue to make efforts to deleverage the Balance Sheet and reduce the Debt without compromising on growth.
- Progress of ongoing Diketene Capex is as per schedule, and is expected to be commissioned during the Quarter Jan to March 2022.
- Further during the year so far we have committed investment worth Rs. 450 Crore for following growth capex. At peak capacity these investments are expected to generate additional annual revenue of Rs. 900-1,000 Crore at prevailing prices
 - CDMO GMP Facility at Bharuch. (Expected to be in operation during the quarter April to June 2022)
 - Three Multi-Purpose plants of Speciality Chemicals. (Expected to be in operation during the quarter July to Sep 2022)
 - Food Grade Acetic Acid. (Expected to be in operation during the quarter April to June 2022)
 - Acetic Anhydride Plant. (Expected to be in operation during the quarter Jan to Mar 2023)
 - Agro Actives Phase-1. (Expected to be in operation during the quarter Jan to March 2023)
- Our expected capex cash outflow for the year will be in the range of Rs 350 crore.

For More Information



For Investors:

Pavleen Taneja Ph: +91 120 436 1002 | 21 E-mail: pavleen.taneja@jubl.com Siddharth Rangnekar CDR India Ph: +91 22 6645 1209 E-mail: siddharth@cdr-india.com

For Media:

Sudhakar Safaya Ph: +91 120 436 1034 E-mail: sudhakar.safaya@jubl.com

Clayton Dsouza

Madison Public Relations E-mail: clayton.dsouza@madisonpr.in Phone number: +91 9930011602

Thank you for your time

Jubilant Ingrevia Limited

1A, Sector-16A, Noida - 201 301, Uttar Pradesh, India Email: support@jubl.com | www.jubilantingrevia.com

Our Vision, Values, Promise and Philosophy





Appendix : Income Statement – Q2 & H1'FY22



Particulars ¹	Q2'FY21 ²	Q2'FY22	YoY (%)	H1'FY21 ²	H1'FY22	YoY (%)
Total Revenue from Operations	784	1,223	56%	1,520	2,367	56%
Speciality Chemicals	252	295	17%	509	600	18%
Nutrition & Health Solutions	125	179	43%	274	346	26%
Life Science Chemicals	406	749	84%	737	1,422	93%
Total Expenditure	647	1,027	59%	1,261	1890	50%
Other Income	4	7		8	13	
Segment EBITDA						
Speciality Chemicals	71	71	0%	140	155	11%
Nutrition & Health Solutions	28	35	23%	60	61	3%
Life Science Chemicals	40	103	160%	63	287	353%
Unallocated Corporate (Expenses)/Income	2	-7	(541%)	5	-14	(390%)
Reported EBITDA	140	202	44%	267	490	83%
Depreciation and Amortization	31	31	(1%)	61	62	1%
Finance Cost	17	7.2	(59%)	46	20	(56%)
Profit before Tax (After Exceptional Items)	92	165	79%	160	408	154%
Tax Expenses (Net)	15	54	264%	31	129	319%
РАТ	77	111	43%	130	279	115%
EPS - Face Value Re. 1 (Rs.)	4.8	7.0	43%	8.2	17.6	115%
Segment EBITDA Margins						
Speciality Chemicals	28.1%	24.1%		27.4%	25.9%	
Nutrition & Health Solutions	22.6%	19.5%		21.8%	17.7%	
Life Science Chemicals	9.7%	13.8%		8.6%	20.2%	
Reported EBITDA Margin	17.9%	16.5%		17.6%	20.7%	
Net Margin	9.9%	9.1%		8.5%	11.8%	

1. All figures are in Rs Crore unless otherwise stated

2. - Q2 & H1'FY21 is derived from 3 month of discontinued operation of LSI segment of Jubilant Pharmova Limited on Pro-forma basis

- EPS has been computed on combined profits assuming existence of share capital for full period.